Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI
Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI
In a single-center, open-label, prospective, controlled, clinical study, it is planned to
 include 300 patients hospitalized in the cardiology department of SBHI Penza regional
 clinical hospital n.a. N.N. Burdenko. Recruitment of patients will be carried out at the
 Department of Therapy of the Medical Institute of the Penza State University. Patients
 meeting the inclusion criteria and not meeting the exclusion criteria will be included in the
 study.

 Initially, lipid-lowering treatment with atorvastatin is prescribed at a dose of 80 mg / day
 from the first 24-96 hours of AMI in addition to the standard therapy.

 If there is no achievement of the target level of LDL-C, ≤1.5 mmol / L after 5-6 weeks from
 the AMI onset, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.

 Standard AMI treatment includes dual antiplatelet therapy, ACE inhibitors, beta-blockers (if
 indicated). Prescription of proton pump inhibitors and nitrates is possible (if indicated).

 The total follow-up is 96 weeks. Prescreening - 600 people; screening and randomization - 300
 people. Parameters of electrical myocardial heterogeneity, myocardial deformation
 characteristics, vascular rigidity, and quality of life will be assessed according to the
 study plan.
Methods

 1. Blood chemistry test. Total cholesterol, LDL, HDL, triglycerides, AST, ALT, CPK,
 glucose, CRP, creatinine, glycosylated hemoglobin

 2. 2D and 3D transthoracic echocardiography (Vivid GE 95 Healthcare (USA). 3D speckle
 echocardiography (3DSTE) for a detailed study of the phase-by-phase movement and spatial
 interaction of all muscle layers of the left ventricle in different phases of the
 cardiac cycle to obtain quantitative values of the deformation of the left ventricle
 individual segments in the longitudinal, circumferential and radial directions.

 The analysis of standard indicators of echocardiography: biplane ejection fraction
 according to the Simpson method, 3D ejection fraction, EDV (end-diastolic volume), ESV
 (end-systolic volume) and their indices. The left ventricular myocardial mass index
 (LVMI).

 Using a tissue doppler, the parameters characterizing the diastolic function are
 recorded: the LA volume, the early diastolic velocity of the mitral valve fibrous ring,
 the ratio of the early diastolic transmitral flow E to the average early diastolic speed
 of the fibrous ring e´, and the maximum tricuspid regurgitation rate.

 Myocardial strain is analyzed using specialized software - EchoPac Software Only
 (General Electric Co., 2018). For three-dimensional strain analysis, the left ventricle
 is automatically divided into 17 segments using standard segmentation schemes. The
 software allows obtaining strain values in the endocardial, middle and epicardial layers
 of the myocardium. Over a period of time, indicators for each segment are automatically
 calculated:

 longitudinal strain/strain rate (LS,%/LSR, cm / s-1), circumferential strain/strain rate
 (CS,%/CSR, cm / s-1), radial strain/strain rate(RS,%/RSR, cm / s-1), area strain),
 rotation, rotation along the axis of the left ventricle (Torsion).

 3. Long-term ECG monitoring over 3 leads with an assessment of the parameters of myocardial
 electrical instability A long-term ECG recording (120 hours) in patients with myocardial
 infarction will be performed using the Astrocard ECG system (CJSC Meditek, Russia) with
 3-channel recorders. Long-term recordings will be analyzed separately for 3 time
 intervals: 24, 72 and 120 hours.

 Pauses of rhythm, rhythm disturbances - extrasystole, unstable tachycardia, AF paroxysm
 and atrial flutter, ventricular fibrillation, conduction disturbance will be recorded.

 Assessment of the ST segment dynamics will be carried out with detection of ischemia
 episodes, which will be detected when the ST segment is displaced ≥10 mV from the
 baseline 80 ms after the J point for at least 1 min - episodes of elevation and
 depression of the ST segment.

 According to the long-term ECG monitoring recordings, the following parameters will be
 analyzed (separately for 3 intervals - 24, 72 and 120 hours):

 circadian dynamics of heart rate; late ventricular potentials (LVP); variance and
 duration of the QT interval; heart rate variability (HRV); heart rate turbulence (TCP);
 chronotropic load (CL). Circadian dynamics of heart rate. The circadian dynamics of
 heart rate will be analyzed with an estimate of the minimum, average and maximum heart
 rate per day, during waking hours and night sleep. The circadian index (CI) will be
 defined as the ratio of the average heart rate in the daytime and the average heart rate
 in the night.

 LVP. The LVP will be evaluated in the standard averaging mode in the range of 40-100 Hz
 by the noise level not exceeding 0.9 μV. Records of the 24-h ECG in patients who have a
 decrease in intraventricular conduction, bundle branches blockade, will not be subjected
 to LVP analysis. An automatic analysis of late post-depolarization begins with a search
 for the QRS reference complex, which will be used later as a reference for averaging.
 Subsequently, the ECG signal will be processed programmatically by the time analysis
 method, at the end of which the following parameters will be evaluated: the width of the
 filtered QRS complex (QRSf), the duration of the low-amplitude potentials at the end of
 the QRS complex of the final part of the complex (HFLA), the rms value of the last 40 ms
 QRS (RMS ) Dispersion and QT interval duration. For a detailed study of the
 repolarization process in the analysis of records, close attention will be paid to the
 analysis of the duration, variability and variance of the QT interval.

 HRV. The following HRV time indicators will be considered:

 -  Mean NN (ms) - average value of all RR-intervals;

 -  SDNN (ms) - standard deviation of the average values of RR-intervals;

 -  SDNNi (ms) - average value of standard deviations RR for 5-minute recording
 periods;

 -  SDANN (ms) is the standard deviation of the mean values of the sinus intervals RR
 for 5 min;

 -  rMSSD (ms) is the square root of the sum of the differences of subsequent RR
 intervals;

 -  pNN50 (%) is the percentage of successive RR intervals differing by more than 50
 ms;

 -  HRVti - triangular index;

 -  TINN is the index of triangular interpolation of the histogram of RR-intervals.

 HRV frequency parameters:

 -  TotP (ms2) is the power of the total spectrum;

 -  ULfP (ms2) - spectrum power in the ultralow frequency range;

 -  VLfP (ms2) is the power of the spectrum within very low frequencies;

 -  LfP (ms2) - low-frequency range of frequencies; HfP (ms2) - high-frequency
 component of HRV; L / H - an indicator of the balance of the vagosympathetic
 balance. Evaluation of the above HRV parameters will be carried out per day, night
 and day hours.

 TCP is characterized by two independent parameters - the beginning of turbulence (TO)
 and the slope of turbulence (TS).

 Heart CL is assessed by the level and duration of exceeding the actual (observed in the
 patient during monitoring) heart rate values of the threshold heart rate calculated
 individually according to the proposed formulas with differentiation for periods of
 wakefulness and night sleep:

 THR-W (bpm) = HRmax (bpm) × 0.45, where THR-W is the threshold value of the heart rate
 during wakeful hours in beats per minute, heart rate max is the age-appropriate value of
 the maximum possible heart rate in beats per minute, 0.45 is the coefficient of the
 threshold level of heart rate; THR-S (bpm) = THR-W (bpm): 1.24, where THR-S (bpm) is the
 threshold value of the heart rate during the night's sleep.

 4. Ultrasound of the common carotid arteries with RF high frequency signal technology The
 study of local vascular stiffness by high-frequency RF signal technology using
 ultrasound of the common carotid arteries (CCA) will be carried out in B mode using
 MyLab 90 (Esaote, Italy).

 The RF signal technology includes two programs: RF-QIMT and RF-QAS. The following CCA
 indicators are analyzed: IMT - intima-media thickness, loc Psys - local systolic
 pressure in the carotid artery, loc Pdia - local diastolic pressure, P (T1) - pressure
 at the local point, stiffness indices β and α, DC is the coefficient of lateral
 distensibility, CC - coefficient of lateral compliance, Aix is the augmentation index,
 AP is the amplification pressure, PWV is the local pulse wave velocity in the carotid
 artery.

 5. Ultrasound of the brachiocephalic and femoral arteries The brachiocephalic and femoral
 arteries will be scanned using a Vivid GE 95 ultrasound scanner (Healthcare, USA) using
 a linear sensor in B-mode, spectral Doppler imaging and color Doppler imaging.

 Quantitative analysis of atherosclerotic plaque includes determining the extent and
 degree of narrowing of the lumen of the vessel (percentage of stenosis) by the
 cross-sectional area (Sa) of the vessel:

 Sa = (A1 - A2) × 100% / A1, where A1 is the true cross-sectional area of the vessel, A2
 is the passable cross-sectional area of the vessel.

 6. Applanation tonometry. SphygmoCor apparatus (AtCor Medical, Australia) uses pulsed wave
 to calculate the characteristics of central pressure in aorta.

 The applanation tonometry technique includes two programs: PWA and PWV. The first allows
 to record central aortic pressure indicators: systolic aortic pressure - SBPao,
 diastolic - DBPao, pulse - PPao, mean hemodynamic - MBPao based on registration of the
 radial artery PWV. Using the PWV program, sequential recording of PWV from the common
 carotid and femoral arteries simultaneously with the ECG channel analyzes the PWV in the
 aorta (cfPWV).

 7. Volume sphygmography. The measurements will be carried out with the VS-1000 device
 (Fukuda Denshi, Japan) while simultaneously recording plethysmograms on four limbs
 (using cuffs), ECG, phonocardiogram, and PWV on the carotid and femoral arteries.

 PWV is evaluated in different parts of the circulatory system (i.e., aorta (PWV),
 predominantly elastic arteries (R/L-PWV) and predominantly muscular arteries (B-PWV)).

 Cardio-Ankle Vascular Index (CAVI) is determined - an indicator that reflects the true
 stiffness of the vascular wall. CAVI is calculated by registering PWV at two points and
 measuring SBP and DBP. Additionally augmentation index and biological age will be
 calculated automatically.

 8. Flow-mediated dilation. Endothelial function is evaluated by ultrasonic determination of
 flow-mediated dilation (FMD) during the postocclusive reactive hyperemia test using the
 method described by D. Celenmajer et. al.

 9. Six-minute walk (6MW) test. The patient should not take cardiological drugs and should
 not smoke within at least 2 hours before the test. Before the 6MW test, the patient
 should have a 10-minute quiet rest in a sitting position. During this rest period, the
 following text should be read to the patient: "You will have to walk for 6 minutes,
 without using continuous running or alternate running and walking, with the aim to cover
 a maximum distance. You will walk back and forth along the corridor. You can slow down
 the pace, stop and have a rest in case of dyspnea or weakness. You can lean against the
 wall during rest. Then, you will have to resume the walk. Remember that your aim is to
 cover maximum distance in 6 minutes." At the 6-minute time point, the patient should be
 asked to stop and stand still until the covered distance has been measured.

 10. Computer Pulse Oximetry. During the 6-minute walk test, computer pulse oximetry is
 planned on a PulseOx 7500 instrument (SPO medical, Israel) to study saturation dynamics
 in comparison groups.

 11. Treatment compliance will be evaluated by standard methods (counting the remaining
 tablets). Morisky-Green Questionnaire

 12. Quality of Life Assessment. The following questionnaires are planned to be completed:
 Seattle Angina Questionnaire (SAQ), Minnesota Questionnaire, Clinical Assessment Scale
 for CHF (MQCAS) (modified by Mareev VY, 2000), analog-visual scale.

 13. Assessment of physical activity. It is planned to fill out a questionnaire for assessing
 the level of physical activity and a short international questionnaire for determining
 the physical activity of the International Questionnaire On Physical Activity - IPAQ

 14. Assessment of Anxiety Depression. An analysis of anxiety and depressive disorders in
 patients using the hospital scale of anxiety and depression (HADS) is planned
Inclusion Criteria:

 1. Signed Informed Consent Form 2 Presence of documented STEMI or NSTEMI / repeated STEMI
 or NSTEMI of LV anterior wall confirmed by ECG, troponin I and CPK-MB levels, coronary
 angiography.

 3. Presence of hemodynamically relevant stenosis of LAD or its branches (diagonal, septal)
 as an infarct-related artery confirmed by CAG.

 Exclusion Criteria:

 1. Presence of hemodynamically relevant stenosis exceeding 30% in several coronary
 arteries confirmed by CAG;

 2. A history of primary STEMI or NSTEMI of the LV posterior wall

 3. Exogenous hypertriglyceridemia (type 1 hyperchilomicronemia).

 4. The development of acute heart failure III-IV prior to randomization

 5. Individual intolerance to statins, ezetimibe.

 6. Congenital and acquired heart diseases.

 7. Severe concomitant diseases in the stage of decompensation.

 8. Non-sinus rhythm, established artificial pacemaker.

 9. Sinoatrial and atrioventricular blockade of 2-3 degrees.

 10. QRS complex exceeding 100 ms.

 11. The presence of severe LV hypertrophy according to echocardiography.

 12. Uncontrolled hypertension with SBP> 180 mm Hg and DBP> 110 mmHg

 13. Diabetes mellitus (DM) type 1 and 2.

 14. Current existence of severe anemia (Hb < 100 g/L)

 15. Chronic kidney disease (creatinine clearance less than 30 ml / min / 1.73 m2 according
 to the CKD-EPI).

 16. Non-corrected thyroid dysfunction with hyper / hypothyroidism.

 17. Body mass index (BMI) ≥35 kg / m2.

 18. Pregnancy, lactation.

 19. Alcohol abuse, drug addiction.

 20. Other serious concomitant diseases that exclude the possibility of study
 participation.

 21. Participation in other clinical trials within the last two months.